Skip to main content
. 2004 Dec 23;563(Pt 3):821–829. doi: 10.1113/jphysiol.2004.080705

Figure 5. Effect of pretreatment with the KATP channel blocker glibenclamide to block the inhibitory action of either cromakalim or nitroprusside on α2-adrenoceptor-induced smRLC phosphorylation.

Figure 5

Glibenclamide prevented the inhibitory action of either cromakalim or nitroprusside on UK 14,304-induced smRLC phosphorylation. Results were similar for soleus and EDL muscles. *P < 0.05 versus glibenclamide alone; n≥ 4 muscles per treatment.